HH
ALNY icon

Hilltop Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hilltop Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,139
Closed -$453K – 642
2025
Q4 		$453K Sell
1,139
-50
-4% -$22.1K 0.03% 580
2025
Q3 		$542K Buy
1,189
+273
+30% +$111K 0.03% 544
2025
Q2 		$299K Buy
+916
New +$253K 0.02% 690

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hilltop Holdings's ALNY Position: Q1 2026 in Review

Hilltop Holdings sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,139 shares — an estimated $453K sold.

Hilltop Holdings first reported a position in ALNY in Q2 2025 and held it in 3 quarters. The position peaked at $542K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Hilltop Holdings reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hilltop Holdings sold 1,139 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $453K.
  • Hilltop Holdings first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Hilltop Holdings's Alnylam Pharmaceuticals position peaked at $542K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Hilltop Holdings's 13F filing for Q1 2026, filed 14 May 2026.